

Rezolute shares rise after FDA feedback on sunRIZE trial; mixed efficacy, data review ahead for rare genetic disorder drug.
You can purchase shares of Rezolute (NASDAQ:RZLT) through any online brokerage.
Other companies in Rezolute’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Rezolute has a consensus price target of $10.36.
The stock price for Rezolute (NASDAQ: RZLT) is $3.855 last updated October 23, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Rezolute.
Rezolute does not have any upcoming earnings scheduled.
There is no upcoming split for Rezolute.
Rezolute is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for...